BioAge Labs Announces First Participant Dosed in QUELL-CV, a Phase 2 Proof-of-Concept Trial of BGE-102, a Novel Oral NLRP3 Inhibitor, in Patients at Elevated Cardiovascular Risk
BioAge Labs dosed the first participant in QUELL-CV, a Phase 2 proof-of-concept trial evaluating its lead asset BGE-102 for cardiovascular risk reduction. The randomized trial will enroll approximately 160 patients across three dose arms to evaluate the drug's effect on hsCRP over 12 weeks, building on Phase 1 data showing 86% median hsCRP reductions.
Key figures
- Drug Name
- BGE-102
- Phase Of Trial
- Phase 2
- Dose levels mg
- [30,60,90]
- Participant count
- 160
- Phase1 normalization pct
- 87–93%
- Treatment duration weeks
- 12
- Phase1 hscrp reduction pct
- 86
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.